Allied Minds Names Kevin Sharer, Former Chairman And CEO Of Amgen, To Board Of Directors

BOSTON--(BUSINESS WIRE)--Allied Minds (LSE: ALM), an innovative U.S. science and technology development and commercialization company, today announced the appointment of Kevin Sharer, the former Chairman and Chief Executive Officer of Amgen, to its Board of Directors.

Sharer led Amgen for two decades, starting as President and Chief Operating Officer in 1992, and then eventually taking over as Chief Executive Officer and Chairman. Amgen has credited Sharer with an expansion that resulted in operations in 55 countries and a more than fourfold increase in revenue to almost $16 billion. During his tenure, the company received regulatory approval for drugs including Neulasta, for preventing infections in cancer patients undergoing chemotherapy; Prolia for osteoporosis; and Xgeva for the prevention of bone complications such as fractures for cancer patients.

Sharer started his career in the Navy, studying aeronautical engineering at the U.S. Naval Academy. He served as Chief Engineer on the USS Memphis, overseeing the ship’s construction and the crew’s training, and later rose to become a Lieutenant Commander. Following his service, Sharer honed his business skills by working at McKinsey & Co. as a consultant, at General Electric Co. in corporate development, and at MCI Telecommunications Corp. as an executive vice president in marketing.

Sharer’s experience as a global leader, as well as a mentor to senior management teams engaged in high-growth strategies, will be a valuable asset for Allied Minds, which is rapidly expanding its portfolio of companies engaged in commercializing innovations developed at top U.S. academic institutions, including Harvard, Yale and New York Universities, as well as federal research centers.

Having recently served on the boards of Chevron Corp. and Northrop Grumman Corp., Sharer is currently a member of the faculty at Harvard Business School, where he teaches, among other things, General Management.

Chris Silva, Chief Executive Officer of Allied Minds, commented: “We are delighted with the appointment of Kevin Sharer to our Board of Directors. He is a seasoned executive with a strong and highly relevant track record of successfully developing and commercializing new and disruptive science and technologies. I am confident that Kevin will further enhance our ability to transform U.S. inventions into commercial innovation.”

Kevin Sharer commented: “I am very pleased to join the Board of Allied Minds. The company is very well positioned to commercialize next-generation technologies, having built an unparalleled network, screening and development approach, and portfolio of subsidiaries. I look forward to working with them to develop existing and new companies around potentially disruptive technologies.”

More information about Allied Minds can be found at www.alliedminds.com.

About Allied Minds
Allied Minds (LSE: ALM) is an innovative U.S. science and technology development and commercialization company. Operating since 2006, Allied Minds forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at www.alliedminds.com.

Allied Minds Forward-Looking Statement
This press release contains statements that are or may be forward-looking statements, including statements that relate to the company’s future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risk and uncertainties described in the risk factors included in the company’s regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Prospectus Rules, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.